Immunosuppressive therapy: Difference between revisions

From IDWiki
No edit summary
m (linkified)
 
(One intermediate revision by the same user not shown)
Line 3: Line 3:
 
Before starting immunosuppressive therapy, consider the following investigations:
  
Before starting immunosuppressive therapy, consider the following investigations:
   
−
* Tuberculin skin test
 +
* [[Tuberculin skin test]]
−
* Strongyloides serology, if from endemic country
 +
* [[Strongyloides]] serology, if from endemic country
−
* Hep B and C serology
 +
* [[Hepatitis B]] and [[Hepatitis C virus|C]] serology
−
* Cytomegalovirus serology
 +
* [[Cytomegalovirus]] serology
−
* HIV serology
 +
* [[HIV]] serology
   
 
== Management ==
  
== Management ==
   
−
* Latent TB infection: start treatment at least 4 weeks prior to starting the biologic
 +
* [[Latent tuberculosis infection|Latent TB infection]]: start treatment at least 4 weeks prior to starting the biologic
   
 
== Specific Medications ==
  
== Specific Medications ==
Line 19: Line 19:
 
! Target
  
! Target
 
!Type
  
!Type
  +
!Indications
 
! Specific Risks
  
! Specific Risks
 
|-
  
|-
 
| [[Eculizumab]]
  
| [[Eculizumab]]
 
| C5 complement
  
| C5 complement
  +
|
 
|
  
|
 
| [[meningococcus]] (very high risk; needs MCV4 + MenB + pen prophylaxis)
  
| [[meningococcus]] (very high risk; needs MCV4 + MenB + pen prophylaxis)
Line 29: Line 31:
 
| CD20
  
| CD20
 
|
  
|
  +
|
−
|specific risk of [[PML]] and [[HBV]]; serious bacterial infections, PML, parvovirus, CMV, HSV, and disseminated VZV infections, HBV and HCV reactivation
  
  +
|specific risk of [[PML]] and [[HBV]]; serious bacterial infections, [[PML]], [[parvovirus]], [[CMV]], [[HSV]], and disseminated [[VZV]] infections, [[HBV]] and [[HCV]] reactivation
 
|-
  
|-
 
|[[Ocrelizumab]]
  
|[[Ocrelizumab]]
 
|CD20
  
|CD20
  +
|
 
|
  
|
 
|
  
|
Line 39: Line 43:
 
| α4-integrin
  
| α4-integrin
 
|humanized IgG4
  
|humanized IgG4
  +
|
−
| specific risk of [[PML]]; herpesvirus infections, influenza, Cryptosporidium diarrhea, bacterial pneumonias and UTIs, PCP, Mycobacterium avium-intracellulare infection, Aspergillus and Burkholderia cepacia infections
  
  +
| specific risk of [[PML]]; [[Herpesviridae|herpesvirus]] infections, [[influenza]], [[Cryptosporidium]] diarrhea, bacterial [[pneumonia]] and [[UTI]], [[Pneumocystis jirovecii|PCP]], [[Mycobacterium avium-intracellulare]] infection, [[Aspergillus]] and [[Burkholderia cepacia]] infections
 
|-
  
|-
 
| [[Ibrutinib]]
  
| [[Ibrutinib]]
 
| Bruton's tyrosine kinase (BTK), on B cells
  
| Bruton's tyrosine kinase (BTK), on B cells
 
|
  
|
  +
|
−
| Invasive aspergillosis and other fungal infections
  
  +
| Invasive [[aspergillosis]] and other [[Invasive fungal infection|fungal infections]]
 
|-
  
|-
 
|Steroids
  
|Steroids
  +
|
 
|
  
|
 
|
  
|
Line 53: Line 60:
 
|[[Cyclosphosphamide]]
  
|[[Cyclosphosphamide]]
 
|Antimetabolite
  
|Antimetabolite
  +
|
 
|
  
|
 
|
  
|
Line 58: Line 66:
 
|[[Leflunomide]]
  
|[[Leflunomide]]
 
|Antimetabolite
  
|Antimetabolite
  +
|
 
|
  
|
 
|
  
|
Line 63: Line 72:
 
|[[Methotrexate]]
  
|[[Methotrexate]]
 
|Antimetabolite
  
|Antimetabolite
  +
|
 
|
  
|
 
|
  
|
Line 68: Line 78:
 
|[[Azathioprine]]
  
|[[Azathioprine]]
 
|Antimetabolite
  
|Antimetabolite
  +
|
 
|
  
|
 
|
  
|
Line 73: Line 84:
 
|[[6-mercaptopurine]]
  
|[[6-mercaptopurine]]
 
|Antimetabolite
  
|Antimetabolite
  +
|
 
|
  
|
 
|
  
|
Line 78: Line 90:
 
|[[Mycophenolic acid]]
  
|[[Mycophenolic acid]]
 
|Antimetabolite
  
|Antimetabolite
  +
|
 
|
  
|
 
|
  
|
Line 83: Line 96:
 
|[[Mycophenolate mofetil]]
  
|[[Mycophenolate mofetil]]
 
|Antimetabolite
  
|Antimetabolite
  +
|
 
|
  
|
 
|
  
|
Line 88: Line 102:
 
|[[Tacrolimus]]
  
|[[Tacrolimus]]
 
|Calcineurin inhibitor
  
|Calcineurin inhibitor
  +
|
 
|
  
|
 
|
  
|
Line 93: Line 108:
 
|[[Cyclosporine]]
  
|[[Cyclosporine]]
 
|Calcineurin inhibitor
  
|Calcineurin inhibitor
  +
|
 
|
  
|
 
|
  
|
Line 98: Line 114:
 
|[[Sirolimus]]
  
|[[Sirolimus]]
 
|Calcineurin inhibitor
  
|Calcineurin inhibitor
  +
|
 
|
  
|
 
|
  
|
Line 103: Line 120:
 
|[[Baricitinib]]
  
|[[Baricitinib]]
 
|JAK inhibitor
  
|JAK inhibitor
  +
|
 
|
  
|
 
|
  
|
Line 108: Line 126:
 
|[[Tofacitinib]]
  
|[[Tofacitinib]]
 
|JAK inhibitor
  
|JAK inhibitor
  +
|
 
|
  
|
 
|
  
|
Line 113: Line 132:
 
|[[Upadacitinib]]
  
|[[Upadacitinib]]
 
|JAK inhibitor
  
|JAK inhibitor
  +
|
 
|
  
|
 
|
  
|
Line 119: Line 139:
 
|TNF-α
  
|TNF-α
 
|human IgG1
  
|human IgG1
  +
|
−
|serious pulmonary bacterial infections, TB, candidiasis, CMV infection, toxoplasmosis, and nocardiosis
  
  +
|serious pulmonary bacterial infections, [[TB]], [[candidiasis]], [[CMV]] infection, [[toxoplasmosis]], and [[nocardiosis]]
 
|-
  
|-
 
|[[Certolizumab pegol]]
  
|[[Certolizumab pegol]]
 
|TNF-α
  
|TNF-α
 
|humanized Fab' fragment
  
|humanized Fab' fragment
  +
|
−
|serious pulmonary bacterial infections, TB, viral and fungal infections
  
  +
|serious pulmonary bacterial infections, [[TB]], viral and fungal infections
 
|-
  
|-
 
|[[Golimumab]]
  
|[[Golimumab]]
 
|TNF-α
  
|TNF-α
  +
|
 
|
  
|
 
|
  
|
Line 133: Line 156:
 
|[[Certolizumab pegol]]
  
|[[Certolizumab pegol]]
 
|TNF-α
  
|TNF-α
  +
|
 
|
  
|
 
|
  
|
Line 139: Line 163:
 
|TNF-α
  
|TNF-α
 
|human dimeric fusion protein
  
|human dimeric fusion protein
  +
|
−
|serious bacterial infections, TB, infections with MOTT, listeriosis, histoplasmosis, candidiasis, aspergillosis, cryptococcosis, nocardiasis, protozoal and VZV infection
  
  +
|serious bacterial infections, [[TB]], [[NTM]], [[listeriosis]], [[histoplasmosis]], [[candidiasis]], [[aspergillosis]], [[cryptococcosis]], [[nocardiasis]], [[Protozoa|protozoal]] and [[VZV]] infection
 
|-
  
|-
 
|[[Infliximab]]
  
|[[Infliximab]]
 
|TNF-α
  
|TNF-α
 
|chimeric IgG1
  
|chimeric IgG1
  +
|
−
|pneumonia, sepsis, TB, infections with MOTT, listeriosis, histoplasmosis, candidiasis, aspergillosis, cryptococcosis, salmonellosis, toxoplasmosis, brucellosis, bartonellosis, leishmaniasis, coccidiomycoses, leprosy, CMV infection, HBV reactivation
  
  +
|[[pneumonia]], [[sepsis]], [[TB]], [[NTM]], [[listeriosis]], [[histoplasmosis]], [[candidiasis]], [[aspergillosis]], [[cryptococcosis]], [[salmonellosis]], [[toxoplasmosis]], [[brucellosis]], [[bartonellosis]], [[leishmaniasis]], [[coccidiomycoses]], [[leprosy]], [[CMV]] infection, [[HBV]] reactivation
 
|-
  
|-
 
|[[Sulfasalazine]]
  
|[[Sulfasalazine]]
 
|Anti-inflammatory
  
|Anti-inflammatory
  +
|
 
|
  
|
 
|
  
|
Line 153: Line 180:
 
|[[5-aminosalicylic acid]] and [[mesalamine]]
  
|[[5-aminosalicylic acid]] and [[mesalamine]]
 
|Anti-inflammatory
  
|Anti-inflammatory
  +
|
 
|
  
|
 
|
  
|
Line 159: Line 187:
 
|IL-1
  
|IL-1
 
|non-glycosylated IL-1 receptor
  
|non-glycosylated IL-1 receptor
  +
|
−
|pneumonia, cellulitis, TB, unspecified mycobacterial and fungal infections
  
  +
|[[pneumonia]], [[cellulitis]], [[TB]], unspecified [[Mycobacteria|mycobacterial]] and fungal infections
 
|-
  
|-
 
|[[Rilonacept]]
  
|[[Rilonacept]]
 
|IL-1
  
|IL-1
 
|dimeric fusion protein IL-1 inhibitor
  
|dimeric fusion protein IL-1 inhibitor
  +
|
−
|meningitis, MOTT infection, severe bronchitis
  
  +
|[[meningitis]], [[NTM]], severe [[bronchitis]]
 
|-
  
|-
 
|[[Canakinumab]]
  
|[[Canakinumab]]
 
|IL-1
  
|IL-1
  +
|
 
|
  
|
 
|
  
|
Line 173: Line 204:
 
|[[Tocilizumab]]
  
|[[Tocilizumab]]
 
|Anti-IL6
  
|Anti-IL6
  +
|
 
|
  
|
 
|
  
|
Line 178: Line 210:
 
|[[Sarilumab]]
  
|[[Sarilumab]]
 
|Anti-IL6
  
|Anti-IL6
  +
|
 
|
  
|
 
|
  
|
Line 183: Line 216:
 
|[[Ustekinumab]]
  
|[[Ustekinumab]]
 
|Anti-IL12/IL23
  
|Anti-IL12/IL23
  +
|
 
|
  
|
 
|
  
|
Line 188: Line 222:
 
|[[Secukinumab]]
  
|[[Secukinumab]]
 
|Anti-IL17
  
|Anti-IL17
  +
|human IgG1κ monoclonal antibody
−
|
  
  +
|[[psoriasis]], [[ankylosing spondylitis]], and [[psoriatic arthritis]]
 
|
  
|
 
|-
  
|-
 
|[[Ixekizumab]]
  
|[[Ixekizumab]]
 
|Anti-IL17
  
|Anti-IL17
  +
|
 
|
  
|
 
|
  
|
Line 198: Line 234:
 
|[[Brodalumab]]
  
|[[Brodalumab]]
 
|Anti-IL17 receptor
  
|Anti-IL17 receptor
  +
|
 
|
  
|
 
|
  
|
Line 203: Line 240:
 
|[[Belimumab]]
  
|[[Belimumab]]
 
|Anti-BLyS
  
|Anti-BLyS
  +
|
 
|
  
|
 
|
  
|
Line 208: Line 246:
 
|[[Guselkumab]]
  
|[[Guselkumab]]
 
|Anti-IL23
  
|Anti-IL23
  +
|
 
|
  
|
 
|
  
|
Line 213: Line 252:
 
|[[Risankizumab]]
  
|[[Risankizumab]]
 
|Anti-IL23
  
|Anti-IL23
  +
|
 
|
  
|
 
|
  
|
Line 219: Line 259:
 
|T-cell costimulation inhibitor
  
|T-cell costimulation inhibitor
 
|fusion protein
  
|fusion protein
  +
|
−
|pneumonia, sepsis, aspergillosis, sinusitis, candidiasis, bronchitis, skin and soft tissue infections, viral infections with HSV and VZV
  
  +
|[[pneumonia]], [[sepsis]], [[aspergillosis]], [[sinusitis]], [[candidiasis]], [[bronchitis]], [[skin and soft tissue infection]], viral infections with [[HSV]] and [[VZV]]
 
|-
  
|-
 
|[[Fingolimod]]
  
|[[Fingolimod]]
 
|Selective T-cell costimulation blocker
  
|Selective T-cell costimulation blocker
  +
|
 
|
  
|
 
|
  
|
Line 228: Line 270:
 
|[[Siponimod]]
  
|[[Siponimod]]
 
|S1PR agonist
  
|S1PR agonist
  +
|
 
|
  
|
 
|
  
|
Line 233: Line 276:
 
|[[Ozanimod]]
  
|[[Ozanimod]]
 
|S1PR agonist
  
|S1PR agonist
  +
|
 
|
  
|
 
|
  
|
Line 238: Line 282:
 
|[[Apremilast]]
  
|[[Apremilast]]
 
|Phosphodiesterase inhibitor
  
|Phosphodiesterase inhibitor
  +
|
 
|
  
|
 
|
  
|
Line 243: Line 288:
 
|[[Vedolizumab]]
  
|[[Vedolizumab]]
 
|Anti-integrin
  
|Anti-integrin
  +
|
 
|
  
|
 
|
  
|
Line 249: Line 295:
 
|CD11a
  
|CD11a
 
|humanized IgG1
  
|humanized IgG1
  +
|
−
|generally mild; pneumonia, cellulitis, abscess, sepsis, Legionella pneumonia, necrotizing fasciitis, TB, PML
  
  +
|generally mild; [[pneumonia]], [[cellulitis]], [[abscess]], [[sepsis]], [[Legionella]] pneumonia, [[necrotizing fasciitis]], [[TB]], [[PML]]
 
|-
  
|-
 
|[[Alefacept]]
  
|[[Alefacept]]
 
|T-cell activation
  
|T-cell activation
 
|fusion protein
  
|fusion protein
  +
|
−
|cellulitis, abscess, wound infections, toxic shock, pneumonia, appendicitis, cholecystitis, gastroenteritis, MOTT infection, influenza virus, HCV, and herpesvirus infections
  
  +
|[[cellulitis]], [[abscess]], wound infections, [[Toxic shock syndrome|toxic shock]], [[pneumonia]], [[appendicitis]], [[cholecystitis]], [[gastroenteritis]], [[NTM]] infection, [[influenza virus]], [[HCV]], and [[Herpesviridae|herpesvirus]] infections
 
|-
  
|-
 
|[[Alemtuzumab]]
  
|[[Alemtuzumab]]
 
|CD52
  
|CD52
 
|humanized IgG1
  
|humanized IgG1
  +
|
−
|causes prolonged lymphopenia; overwhelming bacteremia, pneumonia, meningitis, CMV, VZV, and HSV infections, PCP, PML, adenovirus infection, acanthamebiasis, toxoplasmosis, histoplasmosis, cryptococcosis, aspergillosis, Fusarium infection, Scedosporium infection, BK virus infection, HHV-6 infection, candidiasis, parvovirus infection, mucormycosis, TB, Balamuthia mandrillaris infection, MOTT infection, BCGosis, Rhodococcus infection, HBV reactivation
  
  +
|causes prolonged [[lymphopenia]]; overwhelming [[bacteremia]], pneumonia, [[meningitis]], [[CMV]], [[VZV]], and [[HSV]] infections, [[PCP]], [[PML]], [[adenovirus]] infection, [[acanthamebiasis]], [[toxoplasmosis]], [[histoplasmosis]], [[cryptococcosis]], [[aspergillosis]], [[Fusarium]] infection, [[Scedosporium]] infection, [[BK virus]] infection, [[HHV-6]] infection, [[candidiasis]], [[parvovirus]] infection, [[mucormycosis]], [[TB]], [[Balamuthia mandrillaris]] infection, [[NTM]] infection, [[BCG]]-related infection, [[Rhodococcus]] infection, [[HBV]] reactivation
 
|-
  
|-
 
|[[90Y-ibritumomab tiuxetan|<sup>90</sup>Y-ibritumomab tiuxetan]]
  
|[[90Y-ibritumomab tiuxetan|<sup>90</sup>Y-ibritumomab tiuxetan]]
 
|CD20
  
|CD20
 
|radioconjugated murine IgG1
  
|radioconjugated murine IgG1
  +
|
−
|pneumonia, sepsis, cellulitis, colitis, diarrhea, empyema, osteomyelitis, pericarditis, viral pneumonia and viral hepatitis
  
  +
|[[pneumonia]], [[sepsis]], [[cellulitis]], [[colitis]], [[diarrhea]], [[empyema]], [[osteomyelitis]], [[pericarditis]], viral [[pneumonia]] and [[viral hepatitis]]
 
|-
  
|-
 
|[[131I-tositumomab|<sup>131</sup>I-tositumomab]]
  
|[[131I-tositumomab|<sup>131</sup>I-tositumomab]]
 
|CD20
  
|CD20
 
|radioconjugated murine IgG2
  
|radioconjugated murine IgG2
  +
|
−
|pneumonia, septicemia, bronchitis, skin infections, viral infections
  
  +
|[[pneumonia]], septicemia, [[bronchitis]], skin infections, viral infections
 
|-
  
|-
 
|[[Gemtuzumab ozogamicin]]
  
|[[Gemtuzumab ozogamicin]]
 
|CD33
  
|CD33
 
|humanized IgG4 conjugated to calichaemicin
  
|humanized IgG4 conjugated to calichaemicin
  +
|
−
|causes prolonged neutropenia; sepsis, pneumonia, HSV infection, usual opportunistic infections with neutropenia, unusual pathogens include Staphylococcus hominis, Agrobacterium radiobacter, Acinetobacter lwoffii, Rhodococcus, and Pantoea agglomerans
  
  +
|causes prolonged [[neutropenia]]; [[sepsis]], [[pneumonia]], [[HSV]] infection, usual opportunistic infections with [[neutropenia]], unusual pathogens include [[Staphylococcus hominis]], [[Agrobacterium radiobacter]], [[Acinetobacter lwoffii]], [[Rhodococcus]], and [[Pantoea agglomerans]]
 
|-
  
|-
 
|[[Bevacizumab]]
  
|[[Bevacizumab]]
 
|VEGF
  
|VEGF
 
|humanized IgG1
  
|humanized IgG1
  +
|
−
|severe neutropenia; sepsis, anaerobic liver abscess with Bacteroides fragilis, Fusarium nasal septal infection, endophthalmitis, intraocular injection including Bacillus cereus and coagulase-negative Staphylococcus
  
  +
|severe [[neutropenia]]; sepsis, anaerobic [[liver abscess]] with [[Bacteroides fragilis]], [[Fusarium]] nasal septal infection, [[endophthalmitis]], intraocular injection including [[Bacillus cereus]] and [[coagulase-negative Staphylococcus]]
 
|-
  
|-
 
|[[Cetuximab]]
  
|[[Cetuximab]]
 
|ErbB1
  
|ErbB1
 
|chimeric human-murine IgG1
  
|chimeric human-murine IgG1
  +
|
 
|[[paronychia]] caused by [[Staphylococcus aureus]], [[abscess]], [[sepsis]]
  
|[[paronychia]] caused by [[Staphylococcus aureus]], [[abscess]], [[sepsis]]
 
|-
  
|-
Line 289: Line 343:
 
|ErbB1
  
|ErbB1
 
|human IgG2
  
|human IgG2
  +
|
 
|[[paronychia]], [[abscess]], [[sepsis]]
  
|[[paronychia]], [[abscess]], [[sepsis]]
 
|-
  
|-
Line 294: Line 349:
 
|HER2
  
|HER2
 
|human IgG1
  
|human IgG1
  +
|
 
|[[febrile neutropenia]]
  
|[[febrile neutropenia]]
 
|-
  
|-
Line 299: Line 355:
 
|CD25
  
|CD25
 
|chimeric human-murine IgG1
  
|chimeric human-murine IgG1
  +
|
−
|bacterial, CMV, and HSV infections, aspergillosis, nocardiosis, candidiasis, and protozoal infections
  
  +
|bacterial, [[CMV]], and [[HSV]] infections, [[aspergillosis]], [[nocardiosis]], [[candidiasis]], and [[Protozoa|protozoal infections]]
 
|-
  
|-
 
|[[Daclizumab]]
  
|[[Daclizumab]]
 
|CD25
  
|CD25
 
|humanized IgG1
  
|humanized IgG1
  +
|
−
|nocardiosis, legionellosis, MOTT infection, TB, viral infection with CMV, BK virus, adenovirus, HSV, RSV, or influenza virus, fungal infections with ''Aspergillus'', ''Scedosporium'', ''Cunninghamella'', and ''Candida''
  
  +
|[[nocardiosis]], [[legionellosis]], [[Non-tuberculous mycobacteria|MOTT infection]], [[TB]], viral infection with [[CMV]], [[BK virus]], [[adenovirus]], [[HSV]], [[RSV]], or [[influenza virus]], fungal infections with [[Aspergillus]], [[Scedosporium]], [[Cunninghamella]], and [[Candida]]
 
|-
  
|-
 
|[[Muromonab]]
  
|[[Muromonab]]
 
|CD3
  
|CD3
 
|murine IgG2
  
|murine IgG2
  +
|
−
|bacterial infections, including Listeria, Nocardia, and MOTT infections; infections with Aspergillus, Candida, Cryptococcus, or dermatophytes; PCP; infections with Toxoplasma gondii, CMV, EBV, HSV, hepatitis viruses, VZV, adenovirus, enterovirus, RSV, and parainfluenza virus
  
  +
|bacterial infections, including [[Listeria]], [[Nocardia]], and [[Non-tuberculous mycobacteria|MOTT]] infections; infections with [[Aspergillus]], [[Candida]], [[Cryptococcus]], or [[dermatophytes]]; PCP; infections with [[Toxoplasma gondii]], [[CMV]], [[EBV]], [[HSV]], [[Viral hepatitis|hepatitis viruses]], [[VZV]], [[adenovirus]], [[enterovirus]], [[RSV]], and parainfluenza virus
 
|-
  
|-
 
|[[Abciximab]]
  
|[[Abciximab]]
 
|GPIIb/IIIa
  
|GPIIb/IIIa
 
|Fab' fragment of chimeric human-murine IgG1
  
|Fab' fragment of chimeric human-murine IgG1
  +
|
−
|pneumonia
  
  +
|[[pneumonia]]
 
|-
  
|-
 
|[[Omalizumab]]
  
|[[Omalizumab]]
 
|IgE
  
|IgE
 
|humanized IgG1
  
|humanized IgG1
  +
|
 
|none
  
|none
 
|-
  
|-
Line 324: Line 385:
 
|F protein of [[RSV]]
  
|F protein of [[RSV]]
 
|humanized IgG1
  
|humanized IgG1
  +
|
 
|[[otitis media]]
  
|[[otitis media]]
 
|}
  
|}

Latest revision as of 14:19, 6 June 2023

Screening

Before starting immunosuppressive therapy, consider the following investigations:

Management

Specific Medications

Medications Target Type Indications Specific Risks
Eculizumab C5 complement meningococcus (very high risk; needs MCV4 + MenB + pen prophylaxis)
Rituximab CD20 specific risk of PML and HBV; serious bacterial infections, PML, parvovirus, CMV, HSV, and disseminated VZV infections, HBV and HCV reactivation
Ocrelizumab CD20
Natalizumab α4-integrin humanized IgG4 specific risk of PML; herpesvirus infections, influenza, Cryptosporidium diarrhea, bacterial pneumonia and UTI, PCP, Mycobacterium avium-intracellulare infection, Aspergillus and Burkholderia cepacia infections
Ibrutinib Bruton's tyrosine kinase (BTK), on B cells Invasive aspergillosis and other fungal infections
Steroids
Cyclosphosphamide Antimetabolite
Leflunomide Antimetabolite
Methotrexate Antimetabolite
Azathioprine Antimetabolite
6-mercaptopurine Antimetabolite
Mycophenolic acid Antimetabolite
Mycophenolate mofetil Antimetabolite
Tacrolimus Calcineurin inhibitor
Cyclosporine Calcineurin inhibitor
Sirolimus Calcineurin inhibitor
Baricitinib JAK inhibitor
Tofacitinib JAK inhibitor
Upadacitinib JAK inhibitor
Adalimumab TNF-α human IgG1 serious pulmonary bacterial infections, TB, candidiasis, CMV infection, toxoplasmosis, and nocardiosis
Certolizumab pegol TNF-α humanized Fab' fragment serious pulmonary bacterial infections, TB, viral and fungal infections
Golimumab TNF-α
Certolizumab pegol TNF-α
Etanercept TNF-α human dimeric fusion protein serious bacterial infections, TB, NTM, listeriosis, histoplasmosis, candidiasis, aspergillosis, cryptococcosis, nocardiasis, protozoal and VZV infection
Infliximab TNF-α chimeric IgG1 pneumonia, sepsis, TB, NTM, listeriosis, histoplasmosis, candidiasis, aspergillosis, cryptococcosis, salmonellosis, toxoplasmosis, brucellosis, bartonellosis, leishmaniasis, coccidiomycoses, leprosy, CMV infection, HBV reactivation
Sulfasalazine Anti-inflammatory
5-aminosalicylic acid and mesalamine Anti-inflammatory
Anakinra IL-1 non-glycosylated IL-1 receptor pneumonia, cellulitis, TB, unspecified mycobacterial and fungal infections
Rilonacept IL-1 dimeric fusion protein IL-1 inhibitor meningitis, NTM, severe bronchitis
Canakinumab IL-1
Tocilizumab Anti-IL6
Sarilumab Anti-IL6
Ustekinumab Anti-IL12/IL23
Secukinumab Anti-IL17 human IgG1κ monoclonal antibody psoriasis, ankylosing spondylitis, and psoriatic arthritis
Ixekizumab Anti-IL17
Brodalumab Anti-IL17 receptor
Belimumab Anti-BLyS
Guselkumab Anti-IL23
Risankizumab Anti-IL23
Abatacept T-cell costimulation inhibitor fusion protein pneumonia, sepsis, aspergillosis, sinusitis, candidiasis, bronchitis, skin and soft tissue infection, viral infections with HSV and VZV
Fingolimod Selective T-cell costimulation blocker
Siponimod S1PR agonist
Ozanimod S1PR agonist
Apremilast Phosphodiesterase inhibitor
Vedolizumab Anti-integrin
Efalizumab CD11a humanized IgG1 generally mild; pneumonia, cellulitis, abscess, sepsis, Legionella pneumonia, necrotizing fasciitis, TB, PML
Alefacept T-cell activation fusion protein cellulitis, abscess, wound infections, toxic shock, pneumonia, appendicitis, cholecystitis, gastroenteritis, NTM infection, influenza virus, HCV, and herpesvirus infections
Alemtuzumab CD52 humanized IgG1 causes prolonged lymphopenia; overwhelming bacteremia, pneumonia, meningitis, CMV, VZV, and HSV infections, PCP, PML, adenovirus infection, acanthamebiasis, toxoplasmosis, histoplasmosis, cryptococcosis, aspergillosis, Fusarium infection, Scedosporium infection, BK virus infection, HHV-6 infection, candidiasis, parvovirus infection, mucormycosis, TB, Balamuthia mandrillaris infection, NTM infection, BCG-related infection, Rhodococcus infection, HBV reactivation
90Y-ibritumomab tiuxetan CD20 radioconjugated murine IgG1 pneumonia, sepsis, cellulitis, colitis, diarrhea, empyema, osteomyelitis, pericarditis, viral pneumonia and viral hepatitis
131I-tositumomab CD20 radioconjugated murine IgG2 pneumonia, septicemia, bronchitis, skin infections, viral infections
Gemtuzumab ozogamicin CD33 humanized IgG4 conjugated to calichaemicin causes prolonged neutropenia; sepsis, pneumonia, HSV infection, usual opportunistic infections with neutropenia, unusual pathogens include Staphylococcus hominis, Agrobacterium radiobacter, Acinetobacter lwoffii, Rhodococcus, and Pantoea agglomerans
Bevacizumab VEGF humanized IgG1 severe neutropenia; sepsis, anaerobic liver abscess with Bacteroides fragilis, Fusarium nasal septal infection, endophthalmitis, intraocular injection including Bacillus cereus and coagulase-negative Staphylococcus
Cetuximab ErbB1 chimeric human-murine IgG1 paronychia caused by Staphylococcus aureus, abscess, sepsis
Panitumumab ErbB1 human IgG2 paronychia, abscess, sepsis
Trastuzumab HER2 human IgG1 febrile neutropenia
Basiliximab CD25 chimeric human-murine IgG1 bacterial, CMV, and HSV infections, aspergillosis, nocardiosis, candidiasis, and protozoal infections
Daclizumab CD25 humanized IgG1 nocardiosis, legionellosis, MOTT infection, TB, viral infection with CMV, BK virus, adenovirus, HSV, RSV, or influenza virus, fungal infections with Aspergillus, Scedosporium, Cunninghamella, and Candida
Muromonab CD3 murine IgG2 bacterial infections, including Listeria, Nocardia, and MOTT infections; infections with Aspergillus, Candida, Cryptococcus, or dermatophytes; PCP; infections with Toxoplasma gondii, CMV, EBV, HSV, hepatitis viruses, VZV, adenovirus, enterovirus, RSV, and parainfluenza virus
Abciximab GPIIb/IIIa Fab' fragment of chimeric human-murine IgG1 pneumonia
Omalizumab IgE humanized IgG1 none
Palivizumab F protein of RSV humanized IgG1 otitis media

Further Reading

  • Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev. 2009 Apr;22(2):274-90. doi: 10.1128/CMR.00040-08
Retrieved from "https://idwiki.org/index.php?title=Immunosuppressive_therapy&oldid=9987"
Powered by MediaWiki
Powered by Semantic MediaWiki